Effect of Aromatase Inhibitors on Background Parenchymal Enhancement and Amount of Fibroglandular Tissue at Breast MR Imaging
Authors:
- Valencia KingVKValencia King
- Shari B. GoldfarbSGShari B. Goldfarb
- Jennifer D. BrooksJBJennifer D. Brooks
- Janice S. SungJSJanice S. Sung
- Benjamin F. NulsenBNBenjamin F. Nulsen
- Jolanta E. JozefaraJJJolanta E. Jozefara
- Malcolm C. PikeMPMalcolm C. Pike
- Maura N. DicklerMDMaura N. Dickler
- Elizabeth A. MorrisEMElizabeth A. Morris
- 1 September 2012
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 264 (3) , 670-678
Abstract
To evaluate whether treatment with an aromatase inhibitor (AI) influences background parenchymal enhancement (BPE) or amount of fibroglandular tissue (FGT) at breast magnetic resonance (MR) imaging in postmenopausal women with prior history of breast cancer. A waiver of authorization and patient consent was granted by the institutional review board for this HIPAA-compliant retrospective study. Postmenopausal women with breast cancer and MR imaging findings of the contralateral unaffected breast, before and during 6-12 months of AI treatment (anastrozole, letrozole, or exemestane), between August 1999 and June 2010 were retrospectively identified (n = 149). Two readers performed blinded side-by-side comparison of BPE and MR imaging-depicted FGT before and during treatment. BPE and FGT were classified as the same or greater on one of the two MR studies and by using categorical scales: minimal, mild, moderate, or marked for BPE and fatty, scattered, heterogeneously dense, or dense for FGT. Consensus was reached in cases of disagreement. The sign test was used to conduct a side-by-side comparison of BPE and FGT before and during AI treatment. A decrease in BPE occurred in 33.9% (37 of 109) of women during anastrozole treatment, while an increase occurred in only one (P < .0001); 28 of 37 decreases resulted in a category change of BPE. A decrease in MR imaging-depicted FGT occurred in 5.5% (six of 109) of women, while no increases occurred (P = .031). During letrozole treatment, a decrease in BPE occurred in 46% (15 of 33), while an increase occurred in one woman (P = .0003); a decrease in FGT occurred in only one woman, and no increases occurred. Similar results were seen when women also undergoing chemotherapy were excluded. Only seven women were treated with exemestane. Treatment with 6-12 months of anastrozole or letrozole was associated with decreases in BPE, which occurred in a greater proportion of women than decreases in FGT.Keywords
This publication has 28 references indexed in Scilit:
- Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant AnastrozoleCancer Prevention Research, 2011
- A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal womenBreast Cancer Research and Treatment, 2009
- Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast CancerNew England Journal of Medicine, 2009
- Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast CancerCancer Epidemiology, Biomarkers & Prevention, 2008
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Histologic changes in the breast with menopausal hormone therapy useMenopause, 2008
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98Journal of Clinical Oncology, 2007
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerNew England Journal of Medicine, 2005
- Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialThe Lancet, 2005
- Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed by MR imaging at 1.5 tJournal of Magnetic Resonance Imaging, 1995